BOJI CRO: Subsidiary Guangzhou Huasheng Pharmaceutical has obtained a drug registration certificate

BOJI CRO announced that its subsidiary, Guangzhou Huasheng Pharmaceutical Co., Ltd., has obtained the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for the "Compound Polyethylene Glycol Electrolyte Powder." This drug is suitable for bowel cleansing preparation in adult patients prior to endoscopic or radiological examinations and colon surgeries. According to data from Minet, the sales scale of "Compound Polyethylene Glycol Electrolyte Powder" in public hospitals at the city and county levels in China is approximately 220 million RMB in 2024. The acquisition of the drug registration certificate indicates that the drug has met the relevant national drug review technical standards and can be produced and sold in the domestic market after complying with the requirements of Good Manufacturing Practice